Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
Steiger S, Ehreiser L, Anders J, Anders HJ.
Front Immunol. 2022 Sep 23;13:999704. doi: 10.3389/fimmu.2022.999704. eCollection 2022.
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP.
Lancet. 2016 Sep 17;388(10050):1183-92. doi: 10.1016/S0140-6736(16)31339-3. Epub 2016 Aug 16.
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
van der Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, Elewaut D, Ellis AM, Fleurinck C, Gaffney K, Gensler LS, Haroon N, Magrey M, Maksymowych WP, Marten A, Massow U, Oortgiesen M, Poddubnyy D, Rudwaleit M, Shepherd-Smith J, Tomita T, Van den Bosch F, Vaux T, Xu H.
Ann Rheum Dis. 2023 Apr;82(4):515-526. doi: 10.1136/ard-2022-223595. Epub 2023 Jan 17.
Infectious adverse events in patients with atopic dermatitis treated with baricitinib.
Antonelli F, Malvaso D, Caldarola G, Simone C, Peris K, Chiricozzi A.
Immunotherapy. 2023 Dec;15(18):1521-1529. doi: 10.2217/imt-2023-0078. Epub 2023 Oct 18.
Chronic adenoiditis.
Wang H.
J Int Med Res. 2020 Nov;48(11):300060520971458. doi: 10.1177/0300060520971458.
Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Baraliakos X, Deodhar A, Dougados M, Gensler LS, Molto A, Ramiro S, Kivitz AJ, Poddubnyy D, Oortgiesen M, Vaux T, Fleurinck C, Shepherd-Smith J, de la Loge C, de Peyrecave N, van der Heijde D.
Arthritis Rheumatol. 2022 Dec;74(12):1943-1958. doi: 10.1002/art.42282. Epub 2022 Nov 7.
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T; AJM300 Study Group.
Lancet Gastroenterol Hepatol. 2022 Jul;7(7):648-657. doi: 10.1016/S2468-1253(22)00022-X. Epub 2022 Mar 30.
Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies.
Lombardi A, Saydere A, Ungaro R, Bozzi G, Viero G, Bandera A, Gori A, Mondelli MU.
Int J Infect Dis. 2022 Jul;120:77-82. doi: 10.1016/j.ijid.2022.04.022. Epub 2022 Apr 13.
[RSV and associated diseases].
Casalegno JS.
Rev Prat. 2022 Oct;72(8):S5-S7.
Effect of VBC-1814/7J, a poly-phytocompound, on a non-infectious model of pharyngitis.
Uemura J, Nagpal R, Zerbinati N, Singh B, Marcellino M, Mohania D, Marotta F, He F, Ayala A, Kasugai Y, Catanzaro R.
Exp Ther Med. 2017 Jun;13(6):3075-3080. doi: 10.3892/etm.2017.4332. Epub 2017 Apr 12.
